1681.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 11:08):

Stats
Šios dienos apimtis	1.04M
Vidutinė apimtis	745 602
Rinkos kapitalizacija	4.78B
EPS	HKD0 ( 2024-03-28 )
Last Dividend	HKD0.300 ( 2023-06-08 )
Next Dividend	HKD0 ( N/A )
P/E	5.64
ATR14	HKD0.00800 (0.13%)

Tūris Koreliacija

Ilgas: -0.05 (neutral)

Trumpas: 0.28 (neutral)

Signal:(56.663) Neutral

Consun Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Consun Pharmaceutical Koreliacija - Valiuta/Žaliavos

0.19
( neutral )

0.27
( neutral )

0.91
( very strong )

0.67
( moderate )

0.76
( moderate )

-0.34
( neutral )

Consun Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	HKD2.59B
Bruto pelnas:	HKD1.92B (74.19 %)
EPS:	HKD0.980

FY	2023
Pajamos:	HKD2.59B
Bruto pelnas:	HKD1.92B (74.19 %)
EPS:	HKD0.980

FY	2022
Pajamos:	HKD2.34B
Bruto pelnas:	HKD1.76B (75.35 %)
EPS:	HKD0.860

FY	2021
Pajamos:	HKD2.04B
Bruto pelnas:	HKD1.53B (74.70 %)
EPS:	HKD0.740

Financial Reports:

No articles found.

Consun Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.300 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Consun Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.21 - good (92.12%) | Divividend Growth Potential Score: 5.38 - Stable (7.54%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0480	2014-09-25
Last Dividend	HKD0.300	2023-06-08
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	19	--
Total Paid Out	HKD2.25	--
Avg. Dividend % Per Year	0.00%	--
Score	3.38	--
Div. Sustainability Score	9.21
Div.Growth Potential Score	5.38
Div. Directional Score	7.29	--

Next Divdend (Est)
(2024-06-24)

HKD0.334 Estimate 3.45 %

Dividend Stability

0.28 Very Poor

Dividend Score

3.38

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2885.HK	Ex Dividend Junior	2023-06-15	Annually	0.00%
1501.HK	Ex Dividend Junior	2023-05-24	Annually	0.00%
0552.HK	Ex Dividend Junior	2023-07-03	Annually	0.00%
8062.HK	Ex Dividend Knight	2023-08-17	Annually	0.00%
2003.HK	Ex Dividend Junior	2023-10-17	Annually	0.00%
1075.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%
0151.HK	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
3688.HK	No Dividend Player	2023-05-25	Annually	0.00%
1650.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
0688.HK	Ex Dividend Knight	2023-09-18	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.303	1.500	3.94	5.91	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.227	1.500	8.59	10.00	[0.1 - 1]
payoutRatioTTM	0.265	-1.000	7.35	-7.35	[0 - 1]
currentRatioTTM	2.86	0.800	0.692	0.554	[1 - 3]
quickRatioTTM	2.57	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.838	1.500	0.898	1.347	[0.2 - 2]
debtRatioTTM	0.0921	-1.500	8.46	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.316	2.00	9.89	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.295	2.00	9.85	10.00	[0 - 20]
debtEquityRatioTTM	0.140	-1.500	9.44	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.742	1.000	0.968	0.968	[0.2 - 0.8]
operatingProfitMarginTTM	0.319	1.000	5.62	5.62	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.501	1.000	8.33	8.33	[0.2 - 2]
assetTurnoverTTM	0.470	0.800	-0.198	-0.159	[0.5 - 2]
Total Score				9.21

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.46	1.000	9.55	0	[1 - 100]
returnOnEquityTTM	0.227	2.50	9.10	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.295	2.00	9.90	10.00	[0 - 30]
dividendYielPercentageTTM	8.45	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.316	2.00	9.89	10.00	[0 - 30]
payoutRatioTTM	0.265	1.500	7.35	-7.35	[0 - 1]
pegRatioTTM	-0.0732	1.500	-3.82	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0981	1.000	-0.0486	0	[0.1 - 0.5]
Total Score				5.38

Consun Pharmaceutical

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.